Skip to main content

Table 1 Participant demographics and baseline characteristics

From: Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study

 

Doublet Arms

Triplet Arms

 

Arm 1A (n = 10)

Arm 2A (n = 27)

Pooled (n = 37)

Arm 1B (n = 11)

Arm 2B (n = 27)

Pooled (n = 38)

Age at screening, years

 Mean (SD)

62.6 (9.17)

57.8 (11.80)

59.1 (11.24)

56.5 (10.02)

57.8 (12.07)

57.4 (11.39)

 Median (min, max)

63.5 (44, 74)

59.0 (31, 80)

60.0 (31, 80)

59.0 (41, 71)

61.0 (29, 78)

59.5 (29, 78)

Age group at screening, n (%)

  < 65 years

5 (50.0)

19 (70.4)

24 (64.9)

9 (81.8)

20 (74.1)

29 (76.3)

  ≥ 65 years

5 (50.0)

8 (29.6)

13 (35.1)

2 (18.2)

7 (25.9)

9 (23.7)

Sex, n (%)

 Male

8 (80.0)

16 (59.3)

24 (64.9)

7 (63.6)

17 (63.0)

24 (63.2)

 Female

2 (20.0)

11 (40.7)

13 (35.1)

4 (36.4)

10 (37.0)

14 (36.8)

Race, n (%)

 White

9 (90.0)

21 (77.8)

30 (81.1)

11 (100)

23 (85.2)

34 (89.5)

 Black or African American

1 (10.0)

1 (3.7)

2 (5.4)

0

1 (3.7)

1 (2.6)

 Asian

0

1 (3.7)

1 (2.7)

0

0

0

 Other

0

4 (14.8)

4 (10.8)

0

3 (11.1)

3 (7.9)

Ethnicity, n (%)

 Hispanic/Latino

0

1 (3.7)

1 (2.7)

0

0

0

 Not Hispanic/Latino

10 (100)

21 (77.8)

31 (83.8)

11 (100)

23 (85.2)

34 (89.5)

 Unknown

0

1 (3.7)

1 (2.7)

0

0

0

 Not reported

0

4 (14.8)

4 (10.8)

0

4 (14.8)

4 (10.5)

ECOG PS n (%)

 0

7 (70.0)

13 (48.1)

20 (54.1)

3 (27.3)

11 (40.7)

14 (36.8)

 1

3 (30.0)

14 (51.9)

17 (45.9)

8 (72.7)

16 (59.3)

24 (63.2)

  1. ECOG PS Eastern Cooperative Oncology Group performance status, max maximum, min minimum